COMP <GO>
ABBV vs JNJ // 10Y YIELD & FRED MACRO BETA
AbbVie Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ABBV 7
— JNJ 7
▲ 10Y YIELD & FRED MACRO BETA LEADER: ABBV
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
macro-sensitivity
1.15
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
macro-sensitivity
1.08
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABBV VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABBV | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 70.20% | 67.90% | +2.30 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.00% | 25.50% | +3.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 33.3x | 18.5x | +14.80 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 3.47% | 2.97% | +0.50 | ABBV | /fcf-yield <GO> |
| Operating Margin | 24.60% | 34.70% | -10.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 6.90% | 28.50% | -21.60 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 8.60% | 6.00% | +2.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.27% | 0.00% | +2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.33 | 5.59 | -0.26 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.1 | 62.1 | +3.00 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.15 | 1.08 | +0.07 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 113.1x | 23.0x | +90.10 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $513.86B | $662.49B | -$148.63B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABBV REV | JNJ REV | ABBV GROSS % | JNJ GROSS % | ABBV FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $61.16B | $94.19B | 70.2% | 67.9% | $17.82B | $19.70B |
| FY 2024 | $56.33B | $88.82B | 70.0% | 69.1% | $17.83B | $19.84B |
| FY 2023 | $54.32B | $85.16B | — | — | $20.39B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABBV // BETA 1.15
JNJ // BETA 1.08